Alternative Apomorphine Challenge Test
Objective: To propose a new apomorphine challenge test Background: In the standard apomorphine challenge test, the appropriate dose of apomorphine is established by incremental dosing…The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments
Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration
Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats
Objective: The aim of our study was to investigate the effects of stimulation in the rat entopeduncular nucleus (EPN) on single neuronal activity of the…Apomorphine infusion does not impair cognitive action control in Parkinson’s disease
Objective: We sought to verify that apomorphine infusion did not alter cognitive action control.We sought to verify that apomorphine infusion did not alter cognitive action…Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment
Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)
Objective: To review the unique features of the ongoing Phase 3 trial for APL-130277. Background: Patients with Parkinson’s disease (PD) frequently develop problematic OFF episodes…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase
Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON. This dose is…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- Next Page »